Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
68 hedge funds and large institutions have $35.5M invested in Checkpoint Therapeutics in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 6 closing their positions.
367% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 6
106% more capital invested
Capital invested by funds: $17.2M → $35.5M (+$18.2M)
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
45% more funds holding
Funds holding: 47 → 68 (+21)
5.66% more ownership
Funds ownership: 17.36% → 23.02% (+5.7%)
3% less call options, than puts
Call options by funds: $1.6M | Put options by funds: $1.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.95M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.77M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.31M |
| 4 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$1.12M |
| 5 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$199K |
| 2 |
Renaissance Technologies
New York
|
-$199K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$175K |
| 4 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$89.5K |
| 5 |
Walleye Capital
New York
|
-$72.7K |
CKPT Hedge Fund Activity: Q4 2024 in Review
68 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q4 2024, worth a combined $35.5M — up 106% from $17.2M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CKPT positions and 6 closed out — a net gain of 22 holders — while 21 added to existing stakes and 11 trimmed.
The largest buyer was Armistice Capital, adding an estimated $1.95M. The largest seller was D.E. Shaw & Co, cutting an estimated $199K.
- 68 institutional investors held Checkpoint Therapeutics (CKPT) as of Q4 2024, up from 47 in Q3 2024.
- Funds reported $35.5M of Checkpoint Therapeutics stock for Q4 2024, up 106% quarter-over-quarter.
- 28 funds opened new Checkpoint Therapeutics positions in Q4 2024 and 6 closed out, a net change of +22 holders.
- The largest Checkpoint Therapeutics buyer in Q4 2024 was Armistice Capital, an estimated $1.95M added.
- The largest Checkpoint Therapeutics seller in Q4 2024 was D.E. Shaw & Co, an estimated $199K sold.
Based on aggregated 13F filings for Q4 2024.